Cano Health (OTCPK:CANO.Q) - Aandelenkoers, Nieuws & Analyse

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

CANO.Q Overzicht aandelen

Provides primary care medical services to its members in Florida, the United States.

Over het bedrijf

CANO.Q fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	1/6
Dividenden	0/6

Beloningen

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( $1M )

Zeer volatiele aandelenkoers in de afgelopen 3 maanden

Heeft minder dan 1 jaar cash runway

De winst is de afgelopen 5 jaar met 83.5% per jaar gedaald

+ 1 meer risico

Cano Health, Inc. Concurrenten

Inspire Veterinary Partners

NasdaqCM:IVP

US$1.0m

Ethema Health

OTCPK:GRST

US$5.4m

Regional Health Properties

NYSEAM:RHE

US$3.2m

Innovative MedTech

OTCPK:IMTH

US$12.6m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Cano Health
Historische aandelenkoersen
Huidige aandelenkoers	US$0.24
52 Week Hoogtepunt	US$174.00
52 Week Laag	US$0.10
Bèta	-0.44
11 maand verandering	-22.58%
3 maanden verandering	9.59%
1 Jaar Verandering	-99.83%
33 jaar verandering	-99.98%
5 jaar verandering	n/a
Verandering sinds IPO	-99.98%

Recent nieuws en updates

Recent updates

Cano Health: Common Shareholders Likely To Be Wiped Out In Bankruptcy

Feb 06

Cano Health: Bankruptcy Likely After Dismal Q2 Results And Debt Covenant Violations

Aug 11

Cano Health: CEO Departure Could Be Constructive, New Skipper More So

Jun 20

Cano Health: Key Shareholder Meeting Looms, Stock Undervalued But Volatile

Jun 09

Analyst Estimates: Here's What Brokers Think Of Cano Health, Inc. (NYSE:CANO) After Its First-Quarter Report

May 12

Rendement voor aandeelhouders

	CANO.Q	US Healthcare	US Markt
7D	20.0%	-0.9%	-1.6%
1Y	-99.8%	1.3%	30.1%

Rendement versus industrie: CANO.Q presteerde slechter dan de US Healthcare -sector, die het afgelopen jaar een rendement van 1.3 % opleverde.

Rendement versus markt: CANO.Q presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.1 % opleverde.

Prijsvolatiliteit

Is CANO.Q's price volatile compared to industry and market?
CANO.Q volatility
CANO.Q Average Weekly Movement	34.6%
Healthcare Industry Average Movement	6.7%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.0%

Stabiele aandelenkoers: De aandelenkoers van CANO.Q is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 35% ) van CANO.Q is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2009	2,680	Mark Kent	canohealth.com

Cano Health, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Cano Health zich tot de beurswaarde?
CANO.Q fundamentele statistieken
Marktkapitalisatie	US$1.29m
Inkomsten(TTM)	-US$981.97m
Inkomsten(TTM)	US$2.96b

0.0x

P/S-verhouding

0.0x

Koers/Winstverhouding

Is CANO.Q overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
CANO.Q resultatenrekening (TTM)
Inkomsten	US$2.96b
Kosten van inkomsten	US$2.97b
Brutowinst	-US$13.30m
Overige uitgaven	US$968.67m
Inkomsten	-US$981.97m

Laatst gerapporteerde inkomsten

Mar 31, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-207.63
Brutomarge	-0.45%
Nettowinstmarge	-33.23%
Schuld/Eigen Vermogen Verhouding	-18.2%

Hoe presteerde CANO.Q op de lange termijn?

Bekijk historische prestaties en vergelijking

This company listing is no longer active

CANO.Q Overzicht aandelen

Beloningen

Risicoanalyse

Cano Health, Inc. Concurrenten

NasdaqCM:IVP

US$1.0m

OTCPK:GRST

US$5.4m

NYSEAM:RHE

US$3.2m

OTCPK:IMTH

US$12.6m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

First Motion for Exclusivity Period Extension Approved For Cano Health, Inc.

Fourth Amended Disclosure Statement Approved for Cano Health, Inc.

Fourth Amended Reorganization Joint Plan and Disclosure Statement Filed by Cano Health, Inc.

Third Amended Reorganization Joint Plan and Disclosure Statement Filed by Cano Health, Inc.

Second Amended Reorganization Plan and Disclosure Statement Filed by Cano Health, Inc.

First Amended Joint Reorganization and Disclosure Statement Plan Filed by Cano Health, Inc.

Recent updates

First Motion for Exclusivity Period Extension Approved For Cano Health, Inc.

Fourth Amended Disclosure Statement Approved for Cano Health, Inc.

Fourth Amended Reorganization Joint Plan and Disclosure Statement Filed by Cano Health, Inc.

Third Amended Reorganization Joint Plan and Disclosure Statement Filed by Cano Health, Inc.

Second Amended Reorganization Plan and Disclosure Statement Filed by Cano Health, Inc.

First Amended Joint Reorganization and Disclosure Statement Plan Filed by Cano Health, Inc.

Motion for De Minimis Asset Sale Approved for Cano Health, Inc.

Cano Health, Inc. announced delayed annual 10-K filing

Interim DIP Financing Approved for Cano Health, Inc.

Motion for Joint Administration Filed by Cano Health, Inc.

NYSE to Commence Delisting Proceedings Against Cano Health

Cano Health: Common Shareholders Likely To Be Wiped Out In Bankruptcy

Cano Health, Inc. Filed for Bankruptcy

Cano Health Announces Appointment of Two New Independent Directors

Cano Health, Inc. announced delayed 10-Q filing

Cano Health, Inc. Reports Unaudited Consolidated Goodwill Impairment Loss for the Third Quarter Ended September 30, 2023

Cano Health, Inc. Reports Unaudited Consolidated Goodwill Impairment Loss for the Third Quarter Ended September 30, 2023

Third quarter 2023 earnings released: US$91.87 loss per share (vs US$23.34 loss in 3Q 2022)

High number of new and inexperienced directors

Cano Health Provides Nasdaq Compliance Update

Cano Health, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Cano Health, Inc. Announces the Resignation of Mark Novell as Chief Accounting Officer

Cano Health Receives NYSE Notification Letter; Plans to Regain Compliance with Listing Rules

Cano Health, Inc. Appoints Mark Kent as Chief Executive Officer

Cano Health, Inc. announced delayed 10-Q filing

Cano Health: Bankruptcy Likely After Dismal Q2 Results And Debt Covenant Violations

Price target decreased by 7.4% to US$2.67

Cano Health, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Cano Health, Inc. Announces Board Changes

Chief Clinical Officer recently sold US$709k worth of stock

Chief Clinical Officer notifies of intention to sell stock

Elliot Cooperstone Issues a Response to Cano Health’s Post-Market Announcement

Cano Health: CEO Departure Could Be Constructive, New Skipper More So

New minor risk - Insider selling

Cano Health, Inc. Announces Chief Executive Officer Changes

Chief Clinical Officer recently sold US$1.2m worth of stock

Cano Health, Inc. Announces Announces Chief Executive Officer Changes

Chief Clinical Officer notifies of intention to sell stock

Elliot Cooperstone Posts Materials to his Website

Cano Health: Key Shareholder Meeting Looms, Stock Undervalued But Volatile

Cano Health, Inc. Appoints Frederick Green as Interim Chief Legal Officer

Cano Health, Inc., Annual General Meeting, Jun 15, 2023

Consensus estimates of losses per share improve by 29%

Elliot Cooperstone Sends a Letter to the Shareholders of Cano Health, Inc

Analyst Estimates: Here's What Brokers Think Of Cano Health, Inc. (NYSE:CANO) After Its First-Quarter Report

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

Cano Health, Inc. Samenvatting

0.0x

0.0x

Inkomsten en omzet